Actively Recruiting
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Led by Anhui Provincial Hospital · Updated on 2025-01-29
70
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma, esophagectomy followed by postoperative radiotherapy is also prevalent in China. Several retrospective studies demonstrated that postoperative radiotherapy could improve the prognosis of patients. Nevertheless, there still existed approximately 11.5% and 17.2% of total patients developing local-regional relapse and hematological metastasis. The result of Checkmate 577 has shown that postoperative immunotherapy of nivolumab could improve the disease-free survival (median Disease-free Survival 29.7 mos vs. 11.0 mos). Therefore, investigators aimed to implement a pilot study to explore the safety and efficacy of combining postoperative radiotherapy and immunotherapy for patients with locally advanced esophageal squamous cell carcinoma after esophagectomy.
CONDITIONS
Official Title
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 to 75 years old
- Have had esophagectomy surgery
- Confirmed diagnosis of esophageal squamous cell carcinoma by pathology
- Pathological cancer stage between pIIb and IVa
- More than 12 lymph nodes removed during surgery
- ECOG performance status of 0 or 1
- Signed informed consent to participate in the study
You will not qualify if you...
- Younger than 18 or older than 75 years old
- Have not had esophagectomy surgery
- Diagnosis of non-squamous cell carcinoma
- Pathological cancer stage of pI, IIa, or IVb
- Fewer than 12 lymph nodes removed during surgery
- ECOG performance status of 2 or 3
- Did not sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provicial Hospital
Hefei, Anhui, China
Actively Recruiting
Research Team
D
Dong Qian, M.D.
CONTACT
D
Dong Qian, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here